Market Place
Sourcing Support
Vaxcyte To Present At 25th Needham Healthcare Conference
07 Apr 2026 //
GLOBENEWSWIRE
Vaxcyte To Present 2025 Financial Results & Business Update
10 Feb 2026 //
GLOBENEWSWIRE
Vaxcyte Closes $632.5M Offering on Underwriters` Full Exercise
02 Feb 2026 //
GLOBENEWSWIRE
Vaxcyte Initiates Public Stock Offering And Pre-Funded Warrants
29 Jan 2026 //
GLOBENEWSWIRE
Vaxcyte taps Thermo Fisher fill-finish capacity in $1B deal
03 Oct 2025 //
FIERCE PHARMA
Vaxcyte To Set Up Fill-Finish Manufacturing In North Carolina
30 Sep 2025 //
GLOBENEWSWIRE
Vaxcyte Reports Second Quarter 2025 Financial Results
06 Aug 2025 //
GLOBENEWSWIRE
Alexandria Real Estate Announces Lease with Vaxcyte at Campus
21 Nov 2024 //
PR NEWSWIRE
Vaxcyte Announces Public Offering of Common Stock and Pre-Funded Warrants
03 Sep 2024 //
GLOBENEWSWIRE
Vaxcyte Appoints John Furey to Board of Directors
02 Jul 2024 //
GLOBENEWSWIRE
Vaxcyte Q1 2024 Results, Business Update
08 May 2024 //
GLOBENEWSWIRE
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
Vaxcyte Announces Closing of $862.5 Million Public Offering
02 Feb 2024 //
GLOBENEWSWIRE
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31
29 Jan 2024 //
PRESS RELEASE
Vaxcyte Appoints Whitney Jones as Chief People Officer
16 Jan 2024 //
GLOBENEWSWIRE
Vaxcyte Provides Progress Update on Potential Best-in-Class PCV Franchise
04 Jan 2024 //
GLOBENEWSWIRE
Vaxcyte Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Vaxcyte to Present at Upcoming Investor Conferences
31 Oct 2023 //
GLOBENEWSWIRE
Vaxcyte Announces FDA Clearance of Investigational NDA for VAX-31
19 Oct 2023 //
GLOBENEWSWIRE
Vaxcyte & Lonza Expand Collaboration for PCVs Vaccine
16 Oct 2023 //
GLOBENEWSWIRE
Vaxcyte Reports Second Quarter 2023 Financial Results & Provides Business Update
08 Aug 2023 //
GLOBENEWSWIRE
Vaxcyte Mourns the Sudden Passing of Board Member Michael Kamarck
06 Jul 2023 //
PRESS RELEASE
Vaxcyte Reports 1Q 2023 FYR and Provides Business Update
08 May 2023 //
GLOBENEWSWIRE
Vaxcyte Announces Closing of $575 M PO Including Full Exercise of Underwriters
21 Apr 2023 //
GLOBENEWSWIRE
Vaxcyte Announces Pricing of $500 Million Public Offering
19 Apr 2023 //
GLOBENEWSWIRE
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock
17 Apr 2023 //
GLOBENEWSWIRE
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
17 Apr 2023 //
PRESS RELEASE
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results
27 Feb 2023 //
GLOBENEWSWIRE
Vaxcyte Announces FDA Clearance of Investigational NDA for VAX-24
21 Feb 2023 //
GLOBENEWSWIRE
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results
16 Feb 2023 //
GLOBENEWSWIRE
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Sutro Biopharma & Vaxcyte Enter into Option Grant Agreement for the Development
20 Dec 2022 //
GLOBENEWSWIRE
Vaxcyte Reports 3Q 2022 Financial Results and Provides Business Update
07 Nov 2022 //
GLOBENEWSWIRE
Vaxcyte`s data lead to $600M haul, while Taysha looks to raise cash after Astellas deal
27 Oct 2022 //
ENDPTS
Vaxcyte Announces Pricing of $600 Million Public Offering
26 Oct 2022 //
PRESS RELEASE
Vaxcyte`s 24-valent pneumococcal shot will seek a pivotal win
25 Oct 2022 //
ENPTS
Vaxcyte Reports Data from Ph1/2 Study of 24-Valent Pneumococcal Conjugate
24 Oct 2022 //
GLOBENEWSWIRE
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock
24 Oct 2022 //
GLOBENEWSWIRE
Vaxcyte Expands Executive Leadership Team with Key Appointments
11 Oct 2022 //
GLOBENEWSWIRE
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability
06 Sep 2022 //
GLOBENEWSWIRE
Vaxcyte Reports Q2 2022 Financial Results and Provides Business Update
08 Aug 2022 //
GLOBENEWSWIRE
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Programs
04 Aug 2022 //
GLOBENEWSWIRE
Vaxcyte Completes Enrollment of PII Portion of PI/II Study of VAX-24
12 Jul 2022 //
GLOBENEWSWIRE
Vaxcyte Reports First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Vaxcyte to Participate in Upcoming Investor Conferences in May
03 May 2022 //
GLOBENEWSWIRE
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
05 Apr 2022 //
GLOBENEWSWIRE
Vaxcyte Begins Dosing in Phase 2 Ongoing VAX-24 Phase 1/2 Proof-of-Concept Study
04 Apr 2022 //
GLOBENEWSWIRE
Vaxcyte Reports Q4 and Full Year 2021 Financial Results
28 Feb 2022 //
GLOBENEWSWIRE
Vaxcyte Doses First Participants in Phase 1/2 Study Evaluating VAX-24
23 Feb 2022 //
GLOBENEWSWIRE
Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference
10 Feb 2022 //
GLOBENEWSWIRE
